Skip to content
Home
About
Team
Our Board
Management Team
Clinical Ambassadors
Corporate Governance
Our Name & Brandmark
Care Delivery
Pax Centre
Emerald Clinics
Maritime Health Clinic
Drug and Therapy Development
Psychedelic-Assisted Therapy
Ultra-Pure CBD Medicines
MDMA-inspired Medicines
Research & Data Programs
Investor Hub
Shareholder Communications
News
General News
Blogs
Publications
Investor Updates
In the Media
Contact
Menu
Home
About
Team
Our Board
Management Team
Clinical Ambassadors
Corporate Governance
Our Name & Brandmark
Care Delivery
Pax Centre
Emerald Clinics
Maritime Health Clinic
Drug and Therapy Development
Psychedelic-Assisted Therapy
Ultra-Pure CBD Medicines
MDMA-inspired Medicines
Research & Data Programs
Investor Hub
Shareholder Communications
News
General News
Blogs
Publications
Investor Updates
In the Media
Contact
Sara Polanski
June 14, 2023
“MDMA & Modern Medicine” Podcast with Psychiatrist Dr Ben Sessa
May 31, 2023
Psychedelic Therapy Training Begins with Dr Ben Sessa
May 10, 2023
Study finds Medicinal Cannabis May Have Impact on Quality of Life
April 24, 2023
Emyria Unveils Highest Potency CBD Capsule for FDA Pathway
April 17, 2023
Emyria to Develop Psilocybin Therapy Care Model
April 3, 2023
Aspen Australia & Emyria Agreement for EMD-RX5
March 22, 2023
Strong Recruitment for EMD-RX5 Phase 3 Trial
March 19, 2023
MDMA Analogue Library Expands to Address Mental Health Disorders
March 6, 2023
Emyria partners with Pax Centre for MDMA-assisted therapy
March 2, 2023
Blog: A Passion for Building Companies That Aim to Do Good
Load More
Search
Search
Search
Blogs
General News
In the Media
Information
Investor Updates
Publications
Uncategorised
